(15/37), p=.083).2 Additionally, a high percentage of patients who initially responded to study treatment, but later progressed after treatment withdrawal, regained PGA clear or minimal response following treatment with HUMIRA during the 16 week retreatment phase (55.6 percent (15/27) with 0.8mg/kg re-achieved PGA 0/1).3 HUMIRA treatment had a similar safety profile to methotrexate with no new safety risks identified. 2-3
“Research and treatment options are limited for this young population, so we are pleased to share new data that address a significant need in the treatment of pediatric plaque psoriasis,” said John Medich, Ph.D., vice president, clinical development, immunology, AbbVie. “These Phase 3 data build on more than 16 years of clinical research in HUMIRA, further establishing its safety and efficacy profile, even in young patients.”
Additional HUMIRA data to be presented at WCD include poster presentations on moderate to severe plaque psoriasis, including a five-year interim analysis from a 10-year post-marketing surveillance patient registry (ESPRIT) as well as a subgroup analysis evaluating efficacy of HUMIRA across body weight and body mass index in Chinese patients. Investigational studies of HUMIRA for the treatment of moderate to severe Hidradenitis Suppurtativa (HS) will also be presented. An oral presentation will report the impact of HUMIRA on overall pain and duration of pain response in patients with HS. Additionally, featured posters will highlight HUMIRA pharmacokinetics and an integrated analysis from the HS Phase 3 clinical trials.
Since first gaining approval 12 years ago, HUMIRA has been approved in more than 87 countries. It is currently being used to treat more than 850,000 patients worldwide4 across 12 globally approved indications.1